News

Video

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

Author(s):

Matthew Powell, MD

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Related Content